GLP-1 Daily: Ozempic & Wegovy News
FDA Blocks Two Chinese GLP-1 Ingredient Makers; Obesity-Drug Denials Get Harder to Beat
Monday, October 19, 2026 · 7 min
FDA inspection reports describe mold, insects and hidden records at two Chinese suppliers of compounded semaglutide and tirzepatide ingredients, now on import alert. Plus a Health Affairs Scholar study on first-fill GLP-1 denials, and the EU drug regulator's committee backing Lilly's Foundayo pill.
Listen
Show notes
FDA inspection reports describe mold, insects and hidden records at two Chinese suppliers of compounded semaglutide and tirzepatide ingredients, now on import alert. Plus a Health Affairs Scholar study on first-fill GLP-1 denials, and the EU drug regulator's committee backing Lilly's Foundayo pill.
In this episode
- FDA Flags Chinese GLP-1 Ingredient Suppliers — Kalbir Talwar
“Inspection reports describe a mess at two Chinese facilities supplying active ingredients for compounded GLP-1 drugs. At Chengdu Shengnuo, inspectors noted black mold on equipment, "gross contamination" on floors, and "significant insect activity" in the ceilings.”
- Prescription Denials For GLP-1 Receptor Agonists Across Commercial, Medicare, And Medicaid Coverage, 2018–2024 | Health Affairs Scholar | Oxford Academic — Jia, Miaoqing, Levy, Joseph F, McGinty, Emma E, Tummalapalli, Sri Lekha, Zhang, Yongkang
“Denial was higher in Medicaid than commercial coverage (12.6% versus 5.6%) and for obesity-indicated than diabetes-indicated brands (16.8% versus 6.3%). Among individuals with a denied index claim, 34.1% obtained a paid fill within 90 days, declining from 45.9% (2018) to 24.8%…”
- EMA CHMP Backs Orforglipron (Foundayo): Non-Peptide GLP-1 EU Approval Implications — BSR — Biotech Research
“The positive opinion covers two separate indications. For weight management, EMA's recommendation is based on two studies involving more than 4,740 adults with obesity or overweight. Participants treated with orforglipron for 72 weeks lost approximately 5 to 11 per cent of their…”